SMARCA2 and small cell lung carcinoma: Aligning with our observations in vitro, SCLC-P tumorstreated with AU-24118 exhibited significant degradation of its direct targets(SMARCA2/4 and PBRM1), which ensued in downregulation of POU2F3, POU2F3coactivators, and downstream target GFI1B (Figure3C).